These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 16123773

  • 21. Association between the dopamine transporter gene and the inattentive subtype of attention deficit hyperactivity disorder in Taiwan.
    Shang CY, Gau SS, Liu CM, Hwu HG.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):421-8. PubMed ID: 20800641
    [Abstract] [Full Text] [Related]

  • 22. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS, Guilleminault C, Li HY, Yang CM, Wu YY, Chen NH.
    Sleep Med; 2007 Jan 30; 8(1):18-30. PubMed ID: 17157069
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity.
    Szobot CM, Roman T, Hutz MH, Genro JP, Shih MC, Hoexter MQ, Júnior N, Pechansky F, Bressan RA, Rohde LA.
    Synapse; 2011 Feb 30; 65(2):154-9. PubMed ID: 20593420
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The influence of methylphenidate on the power spectrum of ADHD children - an MEG study.
    Wienbruch C, Paul I, Bauer S, Kivelitz H.
    BMC Psychiatry; 2005 Jul 26; 5():29. PubMed ID: 16042816
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.
    Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P, Erbe R, Pelham WE, Epstein LH.
    J Child Adolesc Psychopharmacol; 2009 Apr 26; 19(2):127-36. PubMed ID: 19364291
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample.
    Cornish KM, Manly T, Savage R, Swanson J, Morisano D, Butler N, Grant C, Cross G, Bentley L, Hollis CP.
    Mol Psychiatry; 2005 Jul 26; 10(7):686-98. PubMed ID: 15809660
    [Abstract] [Full Text] [Related]

  • 31. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD.
    van der Meulen EM, Bakker SC, Pauls DL, Oteman N, Kruitwagen CL, Pearson PL, Sinke RJ, Buitelaar JK.
    J Child Psychol Psychiatry; 2005 Oct 26; 46(10):1074-80. PubMed ID: 16178931
    [Abstract] [Full Text] [Related]

  • 32. Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.
    Roman T, Rohde LA, Hutz MH.
    Am J Pharmacogenomics; 2004 Oct 26; 4(2):83-92. PubMed ID: 15059031
    [Abstract] [Full Text] [Related]

  • 33. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children.
    Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J, Sasvari-Szekely M, Nemoda Z.
    Am J Med Genet B Neuropsychiatr Genet; 2008 Dec 05; 147B(8):1431-5. PubMed ID: 18214865
    [Abstract] [Full Text] [Related]

  • 34. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E.
    Neuropharmacology; 2009 Dec 05; 57(7-8):640-52. PubMed ID: 19715709
    [Abstract] [Full Text] [Related]

  • 35. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample.
    Laucht M, Skowronek MH, Becker K, Schmidt MH, Esser G, Schulze TG, Rietschel M.
    Arch Gen Psychiatry; 2007 May 05; 64(5):585-90. PubMed ID: 17485610
    [Abstract] [Full Text] [Related]

  • 36. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.
    Froehlich TE, Epstein JN, Nick TG, Melguizo Castro MS, Stein MA, Brinkman WB, Graham AJ, Langberg JM, Kahn RS.
    J Am Acad Child Adolesc Psychiatry; 2011 Nov 05; 50(11):1129-1139.e2. PubMed ID: 22024001
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb 05; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 40. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
    Salatino-Oliveira A, Genro JP, Zeni C, Polanczyk GV, Chazan R, Guimarães AP, Callegari-Jacques SM, Rohde LA, Hutz MH.
    Biol Psychiatry; 2011 Aug 01; 70(3):216-21. PubMed ID: 21550019
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.